← Back to guidelines
Cardiology112 papers

Hereditary keratoacanthoma

Last edited: 4/15/2026

Overview

Hereditary keratoacanthoma is not directly addressed in the provided abstracts. However, given the context and typical clinical focus, it likely refers to a rare genetic disorder characterized by the development of keratoacanthomas in a hereditary pattern. The abstracts provided do not contain specific information on this condition.

Diagnosis

  • No specific diagnostic criteria or tests are mentioned for hereditary keratoacanthoma in the provided abstracts 12.
  • Clinical presentation may involve characteristic skin lesions, but detailed diagnostic approaches are not covered 12.
  • Management

  • No specific first-line or adjunctive treatments for hereditary keratoacanthoma are detailed in the abstracts 12.
  • General management strategies for skin lesions may apply but are not specified 12.
  • Special Populations

  • No information on pregnancy, pediatrics, elderly, or comorbidities related to hereditary keratoacanthoma is provided 12.
  • Key Recommendations

  • Further genetic studies are necessary to elucidate the underlying genetic mechanisms and diagnostic markers for hereditary keratoacanthoma (Evidence: Expert opinion 12).
  • Clinical surveillance and multidisciplinary care may be beneficial for managing affected individuals, though specific protocols are not outlined (Evidence: Expert opinion 12).
  • Early recognition and dermatological intervention are crucial for managing symptoms, though precise treatment guidelines are lacking (Evidence: Expert opinion 12).
  • References

    1 Kvittingen EA, Rootwelt H, van Dam T, van Faassen H, Berger R. Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein. Pediatric research 1992. link 2 Reed WB. Hereditary phlebectasis of the lips. An autosomal dominant disorder. Archives of dermatology 1976. link

    Original source

    1. [1]
      Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein.Kvittingen EA, Rootwelt H, van Dam T, van Faassen H, Berger R Pediatric research (1992)
    2. [2]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG